Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC

Phase 3

Completed

Conditions: Metastatic Breast Cancer (MBC)

Interventions: Drug: Gemcitabine
Drug: Docetaxel
Drug: Paclitaxel

First Posted Date: 2005-10-12

Last Posted Date: 2011-09-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 241

Registration Number: NCT00236899

Locations: 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viterbo, Italy

Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2005-10-04

Last Posted Date: 2005-11-03

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 75

Registration Number: NCT00231075

Locations: 🇫🇷
Centre Hospitalier Lyon-sud, Pierre-Bénite, France
🇫🇷
Centre Hosptalier Emile Roux, Eaubonne, France

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Phase 2

Completed

Conditions: Testicular Neoplasms

Interventions: Drug: epirubicin
Procedure: high-dose and autologous stem cell transplantation
Drug: paclitaxel
Drug: etoposide
Drug: ifosfamide
Drug: carboplatin

First Posted Date: 2005-10-04

Last Posted Date: 2011-02-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 50

Registration Number: NCT00231582

Locations: 🇫🇷
Hôpital TENON, Service d'Oncologie Médicale, Paris, France

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2005-09-30

Last Posted Date: 2010-01-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00230451

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Dietary Supplement: Oral Ascorbic Acid
Drug: Paclitaxel
Drug: Carboplatin
Drug: Sodium Ascorbate
Dietary Supplement: Oral Mixed natural Carotenoids with Vitamin A
Dietary Supplement: Vitamin E

First Posted Date: 2005-09-28

Last Posted Date: 2018-06-19

Lead Sponsor: Jeanne Drisko, MD, CNS, FACN

Target Recruit Count: 27

Registration Number: NCT00228319

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Radiation

First Posted Date: 2005-09-27

Last Posted Date: 2017-03-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 39

Registration Number: NCT00226590

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida, United States

Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: paclitaxel

First Posted Date: 2005-09-22

Last Posted Date: 2016-08-30

Lead Sponsor: UNICANCER

Target Recruit Count: 30

Registration Number: NCT00217607

Locations: 🇫🇷
Centre Hospitalier Universitaire Bretonneau de Tours, Tours, France
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France

and more 20 locations